Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Early acquisition history and FoldRx context
Neil places FoldRx/Pfizer's tafamidis in historical context and why it shaped thinking about stabilization.
Play episode from 39:25
Transcript
